FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC: Form 990, tax year 2016

View the entire original 990 at ProPublica ↗

Organization: FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC (EIN 52-1986675)
Tax period: 2016-01-01 to 2016-12-31
Filed: 2017-11-13
IRS object ID: 201733179349307838
Schema version: 2016v3.0
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2017-11-13T16:50:55-06:00	ReturnTs
Tax Period End	2016-12-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	560747981	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	DIXON HUGHES GOODMAN LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	901 EAST CARY STREET SUITE 1000	AddressLine1Txt
City	RICHMOND	CityNm
State Abbreviation	VA	StateAbbreviationCd
ZIP	23219	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2016-01-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	521986675	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	FOUNDATION FOR THE NATIONAL INSTITUTES	BusinessNameLine1Txt
Business Name Line2	OF HEALTH INC	BusinessNameLine2Txt

Field	Value	IRS element (for citing)
Business Name Control	FOUN	BusinessNameControlTxt
Phone	3014025311	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	9650 ROCKVILLE PIKE NO 3411	AddressLine1Txt
City	BETHESDA	CityNm
State Abbreviation	MD	StateAbbreviationCd
ZIP	20814	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	MARIA C FREIRE PHD	PersonNm
Person Title	PRESIDENT	PersonTitleTxt
Phone	3014025311	PhoneNum
Signature	2017-11-13	SignatureDt
Discuss With Paid Preparer	Yes (1)	DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	LORI K COCHRAN	PreparerPersonNm
PTIN	P00853221	PTIN
Phone	8042827636	PhoneNum

Filing Security Information FilingSecurityInformation

IP Address IPAddress

Field	Value	IRS element (for citing)
I Pv4 Address	204.15.98.225	IPv4AddressTxt

Field	Value	IRS element (for citing)
IP	2017-11-13	IPDt
IP Tm	09:49:36	IPTm
IP Timezone	ES	IPTimezoneCd
Filing License Type	P	FilingLicenseTypeCd
At Submission Creation Device Id	02C8C3F183F5FDB5309CFB0B1C4488420EC65632	AtSubmissionCreationDeviceId
At Submission Filing Device Id	303EF2475A1EB3281267E578719A17A3ACA1DFA4	AtSubmissionFilingDeviceId

Field	Value	IRS element (for citing)
Tax	2016	TaxYr
Build TS	2017-02-10 21:41:12Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	MARIA C FREIRE PHD	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	9650 ROCKVILLE PIKE NO 3411	AddressLine1Txt
City	BETHESDA	CityNm
State Abbreviation	MD	StateAbbreviationCd
ZIP	20814	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$144,276,654	GrossReceiptsAmt
Group Return For Affiliates	0	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	HTTP://WWW.FNIH.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	2001	FormationYr
Legal Domicile State	MD	LegalDomicileStateCd
Activity Or Mission	THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH (FNIH) CREATES AND LEADS ALLIANCES AND PUBLIC-PRIVATE PARTNERSHIPS THAT ADVANCE BREAKTHROUGH BIOMEDICAL DISCOVERIES AND IMPROVE THE QUALITY OF PEOPLE'S LIVES.	ActivityOrMissionDesc
Voting Members Governing Body	27	VotingMembersGoverningBodyCnt
Voting Members Independent	26	VotingMembersIndependentCnt
Total Employee	48	TotalEmployeeCnt
Total Volunteers	0	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$33,961,606	PYContributionsGrantsAmt
CY Contributions Grants	$82,860,385	CYContributionsGrantsAmt
PY Program Service Revenue	$194,500	PYProgramServiceRevenueAmt
CY Program Service Revenue	$122,392	CYProgramServiceRevenueAmt
PY Investment Income	$385,451	PYInvestmentIncomeAmt
CY Investment Income	$479,385	CYInvestmentIncomeAmt
PY Other Revenue	$24,552	PYOtherRevenueAmt
CY Other Revenue	$64,980	CYOtherRevenueAmt
PY Total Revenue	$34,566,109	PYTotalRevenueAmt
CY Total Revenue	$83,527,142	CYTotalRevenueAmt
PY Grants And Similar Paid	$43,310,618	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$23,228,128	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$6,530,244	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$6,221,610	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$0	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$0	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$186,542	CYTotalFundraisingExpenseAmt
PY Other Expenses	$9,228,745	PYOtherExpensesAmt
CY Other Expenses	$17,947,728	CYOtherExpensesAmt
PY Total Expenses	$59,069,607	PYTotalExpensesAmt
CY Total Expenses	$47,397,466	CYTotalExpensesAmt
PY Revenues Less Expenses	-$24,503,498	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	$36,129,676	CYRevenuesLessExpensesAmt
Total Assets BOY	$74,645,303	TotalAssetsBOYAmt
Total Assets EOY	$116,383,923	TotalAssetsEOYAmt
Total Liabilities BOY	$8,169,755	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$13,155,593	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$66,475,548	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$103,228,330	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	SEE SCHEDULE O, STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENTTHE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH WAS ESTABLISHED BY THE UNITED STATES CONGRESS TO SUPPORT THE NIH IN ITS MISSION TO IMPROVE HEALTH, BY FORMING AND FACILITATING PUBLIC-PRIVATE PARTNERSHIPS FOR BIOMEDICAL RESEARCH AND TRAINING. THE FOUNDATION BUILDS PARTNERSHIP FOR DISCOVERY AND INNOVATION TO IMPROVE HEALTH.	MissionDesc
Significant New Program Srvc	0	SignificantNewProgramSrvcInd
Significant Change	0	SignificantChangeInd
Expense	$41,864,088	ExpenseAmt
Grant	$22,181,298	GrantAmt
Revenue	$122,392	RevenueAmt
Desc	SEE SCHEDULE O, PROGRAM ONE, RESEARCH PARTNERSHIPSPROGRAM ONE - RESEARCH PARTNERSHIPS -BUILDING DIALOGUE, CONSENSUS AND SOLUTIONS FOR HEALTH THREATS AROUND THE WORLDIN THE EARLY 21ST CENTURY, THE 10/90 GAP WAS AT THE FOREFRONT OF CONVERSATION WITHIN THE GLOBAL HEALTH COMMUNITY. THE GLOBAL FORUM ON HEALTH RESEARCH ASSERTED THAT JUST 10 PERCENT OF MEDICAL RESEARCH WAS DEVOTED TO THE DISEASES THAT CAUSE 90 PERCENT OF THE WORLD'S HEALTH BURDEN. TO FILL THIS GAP, THERE WAS A CRITICAL NEED TO INCREASE RESEARCH ON DISEASES THAT CAUSE MILLIONS OF DEATHS IN THE DEVELOPING WORLD. THE FNIH JOINED THE EFFORT TO REDUCE THE 10/90 GAP IN 2003 AS A FOUNDING MEMBER OF A PROGRAM THAT ADVANCED GLOBAL DISEASE RESEARCH ON A COLOSSAL SCALE. WITH AN INVESTMENT OF $200 MILLION FROM THE BILL & MELINDA GATES FOUNDATION, THE FNIH FORMED ITS LARGEST PARTNERSHIP CALLED THE GRAND CHALLENGES IN GLOBAL HEALTH INITIATIVE (GRAND CHALLENGES). THE GOAL OF THE INITIATIVE WAS TO ENCOURAGE APPLICATION OF THE LATEST SCIENTIFIC INNOVATIONS TO COMBAT THE MOST INTRACTABLE HEALTH PROBLEMS OF THE WORLD'S POOREST COUNTRIES. UNDER GRAND CHALLENGES, THE FNIH MANAGED 20 PROJECTS IN MORE THAN 25 COUNTRIES FOCUSED ON IMPROVING EXISTING AND DEVELOPING NEW VACCINES; CREATING STRATEGIES TO CONTROL THE TRANSMISSION OF DISEASES; DEVELOPING PHARMACEUTICALS AND DELIVERY SYSTEMS THAT MINIMIZE LIKELIHOOD OF RESISTANCE; AND GENERATING METHODS TO CURE CHRONIC INFECTIONS.BY 2016, THE FNIH'S CONTINUED PARTNERSHIP WITH THE BILL & MELINDA GATES FOUNDATION THAT FURTHERED THE WORK OF GRAND CHALLENGES HAD ADVANCED TWO HIGHLY NOVEL TECHNOLOGIES FOR PREVENTING THE SPREAD OF MOSQUITO-BORNE DISEASES TO FIELD TESTING, AND STIMULATED CONSENSUS BUILDING AROUND THE DEVELOPMENT PATHWAY FOR NEW MOSQUITO MODIFICATION TECHNOLOGIES. ELIMINATE DENGUE WAS ONE PROJECT THE FNIH INITIATED UNDER GRAND CHALLENGES. SCOTT O'NEILL, PH.D., THEN AT UNIVERSITY OF QUEENSLAND AND LATER AT MONASH UNIVERSITY, AUSTRALIA, RECEIVED A GRANT FOR RESEARCH IN 2005. SOON AFTER, HE HAD A BREAKTHROUGH MOMENT UPON DISCOVERY THAT THE COMMON WOLBACHIA BACTERIUM COULD BLOCK THE REPLICATION OF THE DENGUE VIRUS WITHIN AEDES AEGYPTI MOSQUITOES, WHICH ARE RESPONSIBLE FOR TRANSMITTING THE DISEASE. BY 2008, HE HAD PRODUCED MOSQUITOES THAT COULD CONSISTENTLY PASS WOLBACHIA TO THEIR OFFSPRING AND BLOCK VIRUS REPLICATION, THEREFORE INTERRUPTING TRANSMISSION OF THE DENGUE VIRUS TO HUMANS. ELIMINATE DENGUE WAS READY FOR SMALL SCALE OUTDOOR RELEASE OF THE MOSQUITOES IN AUSTRALIA BY 2011, VIETNAM BY 2013 AND INDONESIA BY 2014 IN COLLABORATION WITH LOCAL GOVERNMENTS.BY 2016, THE ZIKA VIRUS BECAME A PRIORITY HEALTH CONCERN WORLDWIDE AND ELIMINATE DENGUE RESEARCHERS HAD ANOTHER BREAKTHROUGH. THEY CONFIRMED THAT WOLBACHIA OBSTRUCTS THE SPREAD OF THE ZIKA VIRUS BY MOSQUITOES. SINCE THEN, THE WORLD HEALTH ORGANIZATION CALLED ON ELIMINATE DENGUE TO PROCEED WITH PILOT DEPLOYMENT OF THE TECHNOLOGY AND PROJECT TEAMS ARE SCALING-UP ACTIVITIES IN ANTIOQUIA, COLOMBIA AND RIO DE JANEIRO, BRAZIL.ANOTHER GRAND CHALLENGES GRANT SUPPORTED BY THE FNIH WAS AWARDED IN 2005 TO A PROJECT NOW CALLED TARGET MALARIA. THE PROJECT USES GENETIC MODIFICATION TECHNOLOGY (GENE DRIVE) TO REDUCE MOSQUITOES' ABILITY TO TRANSMIT PARASITES THAT CAUSE DISEASES SUCH AS MALARIA. THE ADVANCEMENT OF THIS TECHNOLOGY IS AT THE FOREFRONT OF GLOBAL DISCUSSIONS AS THE EMERGENCE OF SYSTEMS LIKE CRISPR/CAS9 ARE MAKING GENE DRIVE CONSTRUCTS EASIER TO BUILD. A GRANT WAS AWARDED TO AUSTIN BURT, PH.D., IMPERIAL COLLEGE LONDON, UK, AND HIS TEAM TO SUPPORT WAYS TO PROTECT PEOPLE FROM MALARIA-CARRYING MOSQUITOES. OVER THE NEXT DECADE AND WITH ADDITIONAL FUNDING THROUGH THE FNIH, PROF. BURT DEMONSTRATED THAT GENE DRIVES COULD BE USED TO REDUCE THE REPRODUCTION OF MALARIA MOSQUITOES. BY 2011, THE PROJECT ESTABLISHED FIELD SITES IN AFRICA, NOW COLLABORATING WITH SCIENTISTS IN BURKINA FASO, MALI AND UGANDA. TODAY, TARGET MALARIA CONTINUES TO REFINE ITS GENE DRIVE STRATEGY WITH THE GOAL OF CONTRIBUTING TO THE GLOBAL ERADICATION OF MALARIA. IN ONGOING PARTNERSHIP WITH THE BILL & MELINDA GATES FOUNDATION, PART OF THE FNIH'S ROLE HAS BEEN TO ENSURE THAT THE SCIENTIFIC COMMUNITY EXPLORED THE COMPLEX REGULATORY AND ETHICAL ISSUES SURROUNDING MOSQUITO MODIFICATION TECHNOLOGY. THE FNIH HELPED FUND A NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE STUDY THAT SUPPORTED FURTHER TESTING OF GENE DRIVE APPROACHES, WHILE RECOMMENDING A COLLABORATIVE AND CAUTIONARY APPROACH TO THE RESEARCH AND GOVERNANCE OF THESE TECHNOLOGIES. ADDITIONALLY, THE FNIH HOSTED THE "PROBLEM FORMULATION FOR USE OF GENE DRIVE TECHNOLOGY IN MOSQUITOES" WORKSHOP IN 2016. IT BROUGHT TOGETHER A DIVERSE GROUP OF INTERNATIONAL EXPERTS TO CONDUCT A SYSTEMATIC EVALUATION OF POTENTIAL RISKS ASSOCIATED WITH THE USE OF GENE DRIVE TECHNOLOGY TO REDUCE THE BURDEN OF MALARIA IN AFRICA AND TO CONSIDER THE POTENTIAL FOR UNINTENDED CONSEQUENCES. THIS WORKSHOP DEVELOPED CONSENSUS THAT WILL HELP INFORM THE DESIGN OF FURTHER RESEARCH, GUIDELINES AND REGULATIONS. GRAND CHALLENGES PROPELLED THE FNIH ONTO THE WORLD STAGE, SPURRING ITS RAPID GROWTH. THROUGH THE INITIATIVE, THE FNIH EXPANDED ITS INFRASTRUCTURE BY BRINGING GLOBALLY-RECOGNIZED SCIENTISTS TO THE TEAM AND ESTABLISHING ITS CAPACITY FOR GRANT MAKING. DUE LARGELY TO GRAND CHALLENGES, THE FNIH HAS BECOME INTERNATIONALLY RECOGNIZED FOR ITS INITIATIVES FOCUSED ON OPENING DIALOGUE, DEVELOPING CONSENSUS AND IMPLEMENTING SOLUTIONS FOR HEALTH THREATS THAT AFFECT PEOPLE AROUND THE GLOBE.THE BIOMARKERS CONSORTIUM: SHAPING THE FUTURE OF BIOMEDICAL RESEARCHTHE FNIH BIOMARKERS CONSORTIUM (BC) CELEBRATED 10 YEARS OF COLLABORATION, RESEARCH AND IMPACT ON REGULATORY SCIENCE IN 2016. THIS PUBLIC-PRIVATE PARTNERSHIP MANAGED BY THE FNIH IS HELPING TO CREATE A NEW ERA OF PRECISION MEDICINE AND TO ENABLE THERAPIES THAT ARE BETTER TAILORED FOR PATIENTS. IN 2016, THE BC LAUNCHED FIVE COLLABORATIVE PROJECTS, WHICH ARE DESIGNED TO GENERATE TOOLS THAT WILL ADVANCE THE DEVELOPMENT OF THERAPIES IN CANCER, RHEUMATOID ARTHRITIS, FRAILTY AND HEART DISEASE. CONSORTIUM MEMBERS ALSO CONTINUE TO DEVELOP NEW AND INNOVATIVE PROGRAMS IN THESE AND OTHER DISEASE AREAS ENSURING THE BC WILL PROVIDE DECISION-MAKING TOOLS FOR ADVANCING THERAPIES INTO THE FUTURE. IN ADDITION TO ITS WORK ON DISEASE-SPECIFIC PROJECTS, THE BC RECOGNIZED THAT THE USE OF BIOLOGICAL MARKERS (BIOMARKERS) IN DRUG DEVELOPMENT HAS BEEN PARTICULARLY HAMPERED BY A LACK OF CLEAR, PREDICTABLE AND SPECIFIC REGULATORY CRITERIA FOR THE EVIDENCE REQUIRED TO QUALIFY NEW MARKERS. TO RESOLVE THIS, A GROUP LED BY THE BC DEVELOPED AND RELEASED A "FRAMEWORK FOR DEFINING EVIDENTIARY CRITERIA FOR BIOMARKER QUALIFICATION" IN OCTOBER 2016 AS A TOOL TO HELP ASSESS THE LEVEL OF EVIDENCE NEEDED TO SUPPORT FORMAL REGULATORY QUALIFICATION OF BIOMARKERS AT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA). THE DOCUMENT WAS A RESULT OF A MULTI-STAKEHOLDER EFFORT THAT INCORPORATED INPUT FROM NEARLY 200 SCIENTIFIC LEADERS FROM THE FDA, THE NATIONAL INSTITUTES OF HEALTH (NIH), THE FNIH, THE CRITICAL PATH INSTITUTE (C-PATH), PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) AND MULTIPLE PHARMACEUTICAL COMPANIES. THE FRAMEWORK WILL PROVE USEFUL IN ENABLING MORE PRODUCTIVE DISCUSSIONS BETWEEN BIOMARKER DEVELOPERS AND THE FDA, IMPROVING THE QUALITY OF BIOMARKER QUALIFICATION SUBMISSIONS AND INFORMING FUTURE EFFORTS TO DEVELOP RELEVANT FDA GUIDANCES FOR EVIDENTIARY CRITERIA IN BIOMARKER QUALIFICATION. OVER THE PAST DECADE, THE BC HAS RAISED MORE THAN $70 MILLION FOR PRECOMPETITIVE, COLLABORATIVE PROJECTS THAT INCLUDE PARTICIPANTS FROM THE NIH, THE FDA, NOT-FOR-PROFIT ORGANIZATIONS, ACADEMIC RESEARCH ORGANIZATIONS, AND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES. MORE THAN 20 PROJECTS HAVE BEEN LAUNCHED IN 13 DIFFERENT DISEASE AREAS, RESULTING IN 46 PUBLICATIONS WRITTEN ON BEHALF OF OR SPONSORED BY THE BC. ITS WORK ALSO HAS BEEN INSTRUMENTAL IN TESTING NEW MODELS FOR CLINICAL TRIALS. THE BC SPONSORED ONE OF THE FIRST TRIALS TO USE GENETIC MARKERS TO GUIDE THE SELECTION OF TREATMENTS FROM AMONG MULTIPLE DRUGS IN A SINGLE TRIAL, HELPING ESTABLISH AN ACCELERATED APPROVAL PATHWAY FOR NEW BREAST CANCER MEDICINES. TO DATE, THE WORK OF THE BC HAS SUPPORTED THE ADVANCEMENT OF SIX THERAPEUTICS IN THE DRUG DEVELOPMENT PROCESS AND HELPED GENERATE FOUR SEPARATE FDA GUIDANCE DOCUMENTS. THE BC CAN SOLVE THESE AND OTHER CHALLENGES HEAD-ON BECAUSE IT OFFERS A UNIQUE ENVIRONMENT IN WHICH THE RESOURCES AND SCIENTIFIC EXPERTISE OF ITS PARTNERS CAN BE FREELY SHARED. OVER THE PAST 10 YEARS, BIOMARKERS HAVE BECOME RECOGNIZED AS INDISPENSABLE TOOLS FOR EFFECTIVE DRUG DEVELOPMENT, AND THE BC HAS EQUALLY ESTABLISHED ITSELF AS THE PROVEN MODEL FOR ADVANCING THE SCIENTIFIC VALIDITY AND PRACTICAL UTILITY OF BIOMARKERS IN TREATING PATIENTS. ITS MISSION IS AS RELEVANT AS EVER.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$1,257,933	ExpenseAmt
Grant	$987,480	GrantAmt
Desc	SEE SCHEDULE O, PROGRAM TWO, FELLOWSHIPS AND TRAINING PROGRAMSPROGRAM TWO - FELLOWSHIPS AND TRAINING PROGRAMS - BUILDING A CRITICAL PIPELINE OF CLINICIAN SCIENTISTSACCORDING TO THE AMERICAN MEDICAL ASSOCIATION, THE PERCENTAGE OF PHYSICIANS ENGAGED IN RESEARCH AND TEACHING HAS DECREASED IN PAST DECADES. THIS CONCERNING STATISTIC MEANS THAT THERE ARE FEWER CLINICIAN SCIENTISTS THAT PLAY THE VITAL ROLE OF UNDERSTANDING BASIC BIOLOGY AND SCIENTIFIC DISCOVERY WHILE CONSIDERING THE POTENTIAL BENEFITS TO PATIENTS. SINCE 1998, THE FNIH HAS HELPED BUILD A PIPELINE OF CLINICIAN SCIENTISTS BY SUPPORTING TRAINING PROGRAMS AND FELLOWSHIPS AT THE NATIONAL INSTITUTES OF HEALTH (NIH). THIS WORK BEGAN BY RAISING PRIVATE FUNDS FOR THE NIH CLINICAL RESEARCH TRAINING PROGRAM (CRTP). FOR MORE THAN A DECADE, THE PROGRAM ATTRACTED RESEARCH-ORIENTED MEDICAL, DENTAL AND VETERINARY STUDENTS TO RECEIVE TRAINING AT THE NIH. AN ANALYSIS OF THE PROGRAM FOUND THAT CRTP FOSTERED STUDENT CAREERS, AS NEARLY TWO-THIRDS OF PARTICIPANTS ARE STILL CONDUCTING CLINICAL RESEARCH. TRAINING AT THE NIH CONTINUES THROUGH FNIH-SUPPORTED INITIATIVES, SUCH AS THE AMGEN SCHOLARS PROGRAM, SCHOLAR EDUCATION FUNDED BY THE JAYNE KOSKINAS TED GIOVANIS FOUNDATION FOR HEALTH POLICY, THE SALLIE ROSEN KAPLAN POSTDOCTORAL FELLOWSHIP FOR WOMEN SCIENTISTS IN CANCER RESEARCH AND THE MEDICAL RESEARCH SCHOLARS PROGRAM (MRSP), WHICH HAS FURTHERED THE LEGACY OF CRTP SINCE 2012. IN 2016, 52 STUDENTS PARTICIPATING IN MRSP BEGAN ONE-YEAR TRAINING AT THE NIH, CONDUCTING RESEARCH PROJECTS WITH CLOSE MENTORSHIP FROM INVESTIGATORS IN AREAS INCLUDING CANCER, CARDIOLOGY AND NEUROLOGY. STUDENTS ALSO PARTICIPATED IN WORKSHOPS ON LEADERSHIP, ENTREPRENEURSHIP AND DRUG DEVELOPMENT, IN ADDITION TO CLINICAL TEACHING ROUNDS AT THE NIH CLINICAL CENTER. THE NIH AND THE PRIVATE SECTOR-WITH FUNDS RAISED THROUGH THE FNIH-HAVE SUPPORTED NEARLY 240 FELLOWS THROUGH THE MRSP TO DATE.BEYOND TRAINING PROGRAMS, THE FNIH FUNDS INDIVIDUAL FELLOWS IN THE LABORATORIES OF NIH RESEARCHERS ADVANCING THERAPIES FOR DISEASES SUCH AS CANCER. THE STEPHEN J. SOLARZ MEMORIAL FUND, ESTABLISHED IN 2010, HONORS FNIH BOARD MEMBER NINA SOLARZ'S LATE HUSBAND AND U.S. CONGRESSMAN WHO RECEIVED TREATMENT FOR ESOPHAGEAL CANCER AT THE NATIONAL CANCER INSTITUTE (NCI). THE FUND SUPPORTS FELLOWSHIPS IN THE LABORATORY OF DAVID SCHRUMP, M.D., CHIEF OF THE THORACIC AND GASTROINTESTINAL ONCOLOGY BRANCH IN THE CENTER FOR CANCER RESEARCH OF THE NCI, WHOSE RESEARCH STIMULATES A PATIENT'S IMMUNE SYSTEM INTO FIGHTING AND PREVENTING DIFFERENT TYPES OF NEW CANCER GROWTH. THE TWO-YEAR, FULLY FUNDED FELLOWSHIPS TRAIN POST-DOCTORATE SCIENTISTS AND RESEARCHERS FROM ABROAD SO THEY CAN RETURN TO THEIR HOME COUNTRIES WITH KNOWLEDGE THAT WILL BENEFIT THEIR LOCAL COMMUNITIES.ANOTHER FELLOWSHIP MANAGED BY THE FNIH FOCUSES ON RENAL CELL CANCER RESEARCH-THE MOST COMMON TYPE OF KIDNEY CANCER. THE DEAN R. O'NEILL RENAL CELL CANCER RESEARCH FUND AND THE DR. EDWARD T. RANCIC MEMORIAL FUND FOR CANCER RESEARCH HAVE SPONSORED THE FULL-TIME FELLOW FOR THE LAST 10 YEARS IN THE LABORATORY OF RICHARD W. CHILDS, M.D., SENIOR INVESTIGATOR, LABORATORY OF TRANSPLANTATION IMMUNOTHERAPY, AT THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE. SINCE 2007, LAB FELLOWS, INCLUDING CURRENT FELLOW EMILY LEVY, HAVE ADVANCED WORK IN RENAL CELL CANCER RESEARCH IN HOPES OF FINDING A CURE FOR KIDNEY CANCER.THESE TRAINING PROGRAMS AND FELLOWSHIPS ARE CRITICAL FOR DEVELOPING A PIPELINE OF CLINICIAN SCIENTISTS WHO ARE READY TO MEET THE DEMANDS OF THE CHANGING POPULATION. BUT BEYOND THIS, THEY WILL HELP FURTHER INNOVATION IN BIOMEDICAL RESEARCH FOR YEARS TO COME.	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$390,128	ExpenseAmt
Grant	$59,350	GrantAmt
Desc	SEE SCHEDULE O, PROGRAM THREE, MEMORIALS, AWARDS AND EVENTSPROGRAM THREE - MEMORIALS, AWARDS AND EVENTS - THE FNIH MANAGES AND ORGANIZES SCIENTIFIC MEETINGS, AWARDS AND EVENTS THROUGHOUT THE YEAR. FROM LECTURES AND WORKSHOPS TO COLLABORATIVE SUMMITS, THE FNIH FACILITATED MORE THAN 60 EVENTS IN 2016 THAT SPANNED DOZENS OF FIELDS OF RESEARCH. THIS INCLUDED THE 5TH ANNUAL PRESENTATION OF THE LURIE PRIZE IN BIOMEDICAL SCIENCES, A $100,000 AWARD RECOGNIZING OUTSTANDING ACHIEVEMENT BY A PROMISING YOUNG SCIENTIST IN BIOMEDICAL RESEARCH. IN MAY 2017 THOUGHT LEADERS FROM THE NIH, PIONEERS IN BIOMEDICAL SCIENCE, THE BIOTECH AND PHARMACEUTICAL INDUSTRIES, PHILANTHROPISTS AND BUSINESS EXECUTIVES CONVENED AT THE ORGANIZATION OF AMERICAN STATES IN WASHINGTON, D.C. FOR THE PRESENTATION OF THE LURIE PRIZE AT THE FNIH AWARD CEREMONY. WOLF BLITZER, AWARD-WINNING JOURNALIST AND TELEVISION NEWS ANCHOR, WAS THE EVENING'S MASTER OF CEREMONIES. THE 2017 LURIE PRIZE WAS AWARDED TO DAVID M. SABATINI, M.D., PH.D., MEMBER OF THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH AND PROFESSOR OF BIOLOGY, MASSACHUSETTS INSTITUTE OF TECHNOLOGY. DR. SABATINI DISCOVERED THE MTOR (MECHANISTIC TARGET OF RAPAMYCIN) CELLULAR PATHWAY AS A KEY REGULATOR OF GROWTH AND METABOLISM IN RESPONSE TO NUTRIENTS.	Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp

Field	Value	IRS element (for citing)
Expense	$51,627	ExpenseAmt
Desc	PROGRAM FOUR - CAPITAL PROJECTS - THE FNIH'S CAPITAL PROJECTS ENHANCE THE RESEARCH ENVIRONMENT AT NIH, SUPPORTING AND PROMOTING THE IMPORTANT DISCOVERIES THAT RESULT FROM NIH'S LEADING-EDGE WORK. FOR EXAMPLE, THE FNIH SUPPORTS THE EDMOND J. SAFRA FAMILY LODGE, WHICH PROVIDES ACCOMMODATIONS TO ADULT PATIENTS RECEIVING CARE AT THE NIH CLINICAL CENTER AND THEIR FAMILIES AT NO COST TO THEM. IN ADDITION TO THEIR OWN PRIVATE ROOMS, GUESTS ARE FREE TO USE THE FAMILY LODGE'S MANY AMENITIES: A LIBRARY, A BUSINESS AND TELECOMMUTING CENTER, A FITNESS CENTER, A CHILDREN'S PLAY AREA, SEVERAL LOUNGE AREAS, A HEALING GARDEN, AND A NEWLY RENOVATED KITCHEN. THE FAMILY LODGE IS CONVENIENTLY LOCATED WITHIN WALKING DISTANCE OF THE NIH CLINICAL CENTER AND HAS SERVED THOUSANDS OF FAMILY MEMBERS AND CAREGIVERS.	Desc

Field	Value	IRS element (for citing)
Total Other Prog Srvc Expense	$51,627	TotalOtherProgSrvcExpenseAmt
Total Program Service Expenses	$43,563,776	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (1)	DescribedInSection501c3Ind
Schedule B Required	Yes (1)	ScheduleBRequiredInd
Political Campaign Acty	0	PoliticalCampaignActyInd
Lobbying Activities	0	LobbyingActivitiesInd
Subject To Proxy Tax	0	SubjectToProxyTaxInd
Donor Advised Fund	Yes (1)	DonorAdvisedFundInd
Conservation Easements	0	ConservationEasementsInd
Collections Of Art	0	CollectionsOfArtInd
Credit Counseling	Yes (1)	CreditCounselingInd
Temp Or Permanent Endowments	Yes (1)	TempOrPermanentEndowmentsInd
Report Land Building Equipment	Yes (1)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	0	ReportInvestmentsOtherSecInd
Report Program Related Invst	0	ReportProgramRelatedInvstInd
Report Other Assets	0	ReportOtherAssetsInd
Report Other Liabilities	Yes (1)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (1)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	Yes (1)	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	0	ConsolidatedAuditFinclStmtInd
School Operating	0	SchoolOperatingInd
Foreign Office	0	ForeignOfficeInd
Foreign Activities	Yes (1)	ForeignActivitiesInd
More Than5000 K To Org	Yes (1)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	0	MoreThan5000KToIndividualsInd
Professional Fundraising	0	ProfessionalFundraisingInd
Fundraising Activities	Yes (1)	FundraisingActivitiesInd
Gaming Activities	0	GamingActivitiesInd
Operate Hospital	0	OperateHospitalInd
Grants To Organizations	Yes (1)	GrantsToOrganizationsInd
Grants To Individuals	Yes (1)	GrantsToIndividualsInd
Schedule J Required	Yes (1)	ScheduleJRequiredInd
Tax Exempt Bonds	0	TaxExemptBondsInd
Engaged In Excess Benefit Trans	0	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	0	PYExcessBenefitTransInd
Loan Outstanding	0	LoanOutstandingInd
Grant To Related Person	0	GrantToRelatedPersonInd
Business Rln With Org Mem	0	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	0	BusinessRlnWithFamMemInd
Business Rln With Officer Ent	0	BusinessRlnWithOfficerEntInd
Deductible Non Cash Contri	Yes (1)	DeductibleNonCashContriInd
Deductible Art Contribution	0	DeductibleArtContributionInd
Terminate Operations	0	TerminateOperationsInd
Partial Liquidation	0	PartialLiquidationInd
Disregarded Entity	0	DisregardedEntityInd
Related Entity	0	RelatedEntityInd
Related Organization Ctrl Ent	0	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	0	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	0	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (1)	ScheduleORequiredInd
IRP Document	28	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (1)	BackupWthldComplianceInd
Employee	48	EmployeeCnt
Employment Tax Returns Filed	Yes (1)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	0	UnrelatedBusIncmOverLimitInd
Foreign Financial Account	0	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	0	ProhibitedTaxShelterTransInd
Taxable Party Notification	0	TaxablePartyNotificationInd
Nondeductible Contributions	0	NondeductibleContributionsInd
Quid Pro Quo Contributions	0	QuidProQuoContributionsInd
Form8282 Property Disposed Of	0	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	0	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	0	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	0	IndoorTanningServicesInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	27	GoverningBodyVotingMembersCnt
Independent Voting Member	26	IndependentVotingMemberCnt
Family Or Business Rln	Yes (1)	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	0	DelegationOfMgmtDutiesInd
Change To Org Documents	0	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	0	MaterialDiversionOrMisuseInd
Members Or Stockholders	0	MembersOrStockholdersInd
Election Of Board Members	0	ElectionOfBoardMembersInd
Decisions Subject To Approva	0	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (1)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (1)	MinutesOfCommitteesInd
Officer Mailing Address	0	OfficerMailingAddressInd
Local Chapters	0	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (1)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (1)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (1)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (1)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (1)	WhistleblowerPolicyInd
Document Retention Policy	Yes (1)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (1)	CompensationProcessCEOInd
Compensation Process Other	Yes (1)	CompensationProcessOtherInd
Investment In Joint Venture	0	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ME	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ND	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Field	Value	IRS element (for citing)
Person	DONALD M HILL	PersonNm
Phone	3014025311	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	9650 ROCKVILLE PIKE	AddressLine1Txt
City	BETHESDA	CityNm
State Abbreviation	MD	StateAbbreviationCd
ZIP	20814	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (39 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd
DR STEVEN M PAUL
CHAIRMAN	1.50	Yes (X)	Yes (X)	$0	$0	$0
MR STEVEN C MAYER
TREASURER	2.00	Yes (X)	Yes (X)	$0	$0	$0
THE HON JOHN EDWARD PORTER
VICE-CHAIRMAN FOR POLICY	1.00	Yes (X)	Yes (X)	$0	$0	$0
DR SOLOMON H SNYDER
VICE-CHAIRMAN FOR SCIENCE	0.50	Yes (X)	Yes (X)	$0	$0	$0
MRS WILLIAM MCCORMICK BLAIR JR
SECRETARY	1.00	Yes (X)	Yes (X)	$0	$0	$0
DR MARIA C FREIRE
PRESIDENT AND EXECUTIVE DIRECTOR	40.00	Yes (X)	Yes (X)	$406,597	$0	$26,500
DR PAUL M MONTRONE
BOARD OF DIRECTORS MEMBER	1.00	Yes (X)		$0	$0	$0
DAME JILLIAN SACKLER
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
MRS LILY SAFRA
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR ELLEN V SIGAL
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR CHARLES A SANDERS
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
MRS WILLIAM N CAFRITZ
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR SAMUEL O THIER
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR MARTIN J MURPHY JR
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR KATHY BLOOMGARDEN
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
MS ANN LURIE
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR FREDA C LEWIS-HALL
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
MS NINA SOLARZ
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
MR JAMES H DONOVAN
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR PAUL L HERRLING
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR RONALD L KRALL
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR EDISON T LIU
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR JUDY LANSING KOVLER
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
MR JOEL S MARCUS
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
MR RUSSELL W STEENBERG
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR PAUL STOFFELS
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR THOMAS R INSEL
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR JOSEPH M FECZKO
BOARD OF DIRECTORS MEMBER 1/16-5/16	0.25	Yes (X)		$0	$0	$0
MS ANNE WOJCICKI
BOARD OF DIRECTORS MEMBER 1/16-5/16	0.25	Yes (X)		$0	$0	$0
DR STEPHANIE JAMES
DIRECTOR OF SCIENCE	40.00			$305,588	$0	$26,500	Yes (X)
MR DAVID WHOLLEY
DIRECTOR OF RESEARCH PARTNERSHIPS	40.00			$301,988	$0	$38,035	Yes (X)
MS JULIE TUNE
CHIEF FINANCIAL OFFICER	40.00			$201,681	$0	$31,703	Yes (X)
MS JULIA WOLF-RODDA
DIRECTOR OF DEVELOPMENT	40.00			$199,264	$0	$31,461	Yes (X)
MR KEVIN A KLOCK
DIR. OF OPERATIONS & PRESIDENT ADVISOR	40.00			$199,267	$0	$31,462	Yes (X)
DR JOSEPH MENETSKI
DEPUTY DIRECTOR OF RESEARCH PARTNERSHIPS	40.00			$200,877	$0	$31,527		Yes (X)
DR KAREN TOUNTAS
SCIENTIFIC PROGRAM MANAGER	40.00			$169,024	$0	$28,437		Yes (X)
DR MICHAEL GOTTLIEB
ASSOCIATE DIRECTOR OF SCIENCE	40.00			$160,295	$0	$16,030		Yes (X)
DR ROSA CANET AVILES
SCIENTIFIC PROGRAM MANAGER	40.00			$157,635	$0	$27,298		Yes (X)
MR STEVE HOFFMANN
SCIENTIFIC PROGRAM MANAGER	40.00			$144,738	$0	$26,009		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$2,446,954	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$314,962	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	21	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	0	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (1)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	0	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
SWOG CTI
24 FRANK LLOYD WRIGHT DRIVE PO BOX	ANN ARBOR	MI	48105	CONDUCTS CLINICAL TRIAL FOR LUNGMAP	$4,129,601
AVID RADIOPHARMACEUTICALS INC
3711 MARKET STREET 7TH FLOOR	PHILADELPHIA	PA	19104	CONDUCTS CLINICAL TRIAL FOR AMP AD	$481,500
BUSINESS TALENT GROUP LLC
406 BLACKWELL ST SUITE 240A	DURHAM	NC	27701	CONSULTING SERVICES FOR SUPPORT FUNCTION	$467,064
MARRIOTT BUSINESS SERVICES
PO BOX 402642	ATLANTA	GA	30384	MEETING SERVICES FOR VARIOUS PROJECTS	$360,908
ICON EARLY PHASE SERVICES LLC
PO BOX 28939	NEW YORK	NY	10087	CONDUCTS CLINICAL TRIAL FOR ABSSI CARP A	$325,674

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	16	CntrctRcvdGreaterThan100KCnt
Fundraising	$15,500	FundraisingAmt
Government Grants	$1,150,000	GovernmentGrantsAmt
All Other Contributions	$81,694,885	AllOtherContributionsAmt
Noncash Contributions	$754,570	NoncashContributionsAmt
Total Contributions	$82,860,385	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

Field	Value	IRS element (for citing)
Desc	ADMINISTRATIVE FEES	Desc
Business	561000	BusinessCd
Total Revenue Column	$122,392	TotalRevenueColumnAmt
Related Or Exempt Func Income	$122,392	RelatedOrExemptFuncIncomeAmt

Field	Value	IRS element (for citing)
Total Program Service Revenue	$122,392	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$574,125	TotalRevenueColumnAmt
Exclusion	$574,125	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Other	$60,455,452	OtherAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Other	$60,550,192	OtherAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Other	-$94,740	OtherAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$94,740	TotalRevenueColumnAmt
Exclusion	-$94,740	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$264,300	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$15,500	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$199,320	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$64,980	TotalRevenueColumnAmt
Exclusion	$64,980	ExclusionAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$83,527,142	TotalRevenueColumnAmt
Related Or Exempt Func Income	$122,392	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$544,365	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$22,000,760	TotalAmt
Program Services	$22,000,760	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$8,100	TotalAmt
Program Services	$8,100	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$1,219,268	TotalAmt
Program Services	$1,219,268	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$1,792,412	TotalAmt
Program Services	$747,407	ProgramServicesAmt
Management And General	$1,026,634	ManagementAndGeneralAmt
Fundraising	$18,371	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$3,169,479	TotalAmt
Program Services	$1,984,475	ProgramServicesAmt
Management And General	$1,098,349	ManagementAndGeneralAmt
Fundraising	$86,655	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$346,472	TotalAmt
Program Services	$186,729	ProgramServicesAmt
Management And General	$145,025	ManagementAndGeneralAmt
Fundraising	$14,718	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$585,472	TotalAmt
Program Services	$352,135	ProgramServicesAmt
Management And General	$223,935	ManagementAndGeneralAmt
Fundraising	$9,402	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$327,775	TotalAmt
Program Services	$158,591	ProgramServicesAmt
Management And General	$169,184	ManagementAndGeneralAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$120,295	TotalAmt
Program Services	$111,052	ProgramServicesAmt
Management And General	$9,243	ManagementAndGeneralAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$52,935	TotalAmt
Management And General	$52,935	ManagementAndGeneralAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$101,900	TotalAmt
Program Services	$31,083	ProgramServicesAmt
Management And General	$70,817	ManagementAndGeneralAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$7,000	TotalAmt
Program Services	$7,000	ProgramServicesAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$25,288	TotalAmt
Program Services	$12,293	ProgramServicesAmt
Management And General	$12,985	ManagementAndGeneralAmt
Fundraising	$10	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$148,799	TotalAmt
Program Services	$66,153	ProgramServicesAmt
Management And General	$64,991	ManagementAndGeneralAmt
Fundraising	$17,655	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$473,081	TotalAmt
Program Services	$189,410	ProgramServicesAmt
Management And General	$283,671	ManagementAndGeneralAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$1,474,382	TotalAmt
Program Services	$1,391,423	ProgramServicesAmt
Management And General	$78,349	ManagementAndGeneralAmt
Fundraising	$4,610	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$20,094	TotalAmt
Management And General	$20,094	ManagementAndGeneralAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$190,673	TotalAmt
Program Services	$141,179	ProgramServicesAmt
Management And General	$49,494	ManagementAndGeneralAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
PROGRAM CONTRACTS	$13,538,016	$13,538,016
CONSULTANTS	$1,615,064	$1,456,645	$152,669	$5,750
HONORARIA	$121,600	$121,600
TEMPORARY SERVICES	$96,946	$74,011	$22,088	$847

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	-$38,345	TotalAmt
Program Services	-$233,554	ProgramServicesAmt
Management And General	$166,685	ManagementAndGeneralAmt
Fundraising	$28,524	FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$47,397,466	TotalAmt
Program Services	$43,563,776	ProgramServicesAmt
Management And General	$3,647,148	ManagementAndGeneralAmt
Fundraising	$186,542	FundraisingAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$21,131,272	BOYAmt
EOY	$46,693,317	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$10,084,867	BOYAmt
EOY	$26,338,796	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$84,024	BOYAmt
EOY	$90,770	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$692,845	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$650,240	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$50,340	BOYAmt
EOY	$42,605	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$43,250,167	BOYAmt
EOY	$43,080,177	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$44,633	BOYAmt
EOY	$138,258	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$74,645,303	BOYAmt
EOY	$116,383,923	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$1,460,257	BOYAmt
EOY	$8,076,645	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$5,975,257	BOYAmt
EOY	$4,474,530	EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

Field	Value	IRS element (for citing)
BOY	$577,271	BOYAmt
EOY	$453,876	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$156,970	BOYAmt
EOY	$150,542	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$8,169,755	BOYAmt
EOY	$13,155,593	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows SFAS117	Yes (X)	OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$11,662,389	BOYAmt
EOY	$13,322,940	EOYAmt

Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$51,608,294	BOYAmt
EOY	$86,811,639	EOYAmt

Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$3,204,865	BOYAmt
EOY	$3,093,751	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$66,475,548	BOYAmt
EOY	$103,228,330	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$74,645,303	BOYAmt
EOY	$116,383,923	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	$36,129,676	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	$623,106	NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets	$0	OtherChangesInNetAssetsAmt
Info In Schedule O Part XII	Yes (X)	InfoInScheduleOPartXIIInd
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	0	AccountantCompileOrReviewInd
FS Audited	Yes (1)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Separate Basis Fincl Stmt	Yes (X)	SeparateBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (1)	AuditCommitteeInd
Federal Grant Audit Required	0	FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$58,869,026	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$59,135,001	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$73,905,546	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$33,961,607	CurrentTaxYearMinus1YearAmt
Current Tax Year	$82,860,385	CurrentTaxYearAmt
Total	$308,731,565	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$58,869,026	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$59,135,001	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$73,905,546	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$33,961,607	CurrentTaxYearMinus1YearAmt
Current Tax Year	$82,860,385	CurrentTaxYearAmt
Total	$308,731,565	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$154,311,898	SubstantialContributorsTotAmt
Public Support Total170	$154,419,667	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$140,900	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$213,728	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$214,303	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$367,897	CurrentTaxYearMinus1YearAmt
Current Tax Year	$574,125	CurrentTaxYearAmt
Total	$1,510,953	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$310,242,518	TotalSupportAmt
Gross Receipts Rltd Activities	$1,208,504	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.49770	PublicSupportCY170Pct
Public Support PY170	0.46450	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Donor Advised Funds Held	2	DonorAdvisedFundsHeldCnt
Donor Advised Funds Contri	$2,525	DonorAdvisedFundsContriAmt
Donor Advised Funds Grants	$3,100	DonorAdvisedFundsGrantsAmt
Donor Advised Funds Vl EOY	$3,732,287	DonorAdvisedFundsVlEOYAmt
Disclosed Org Leg Ctrl	Yes (1)	DisclosedOrgLegCtrlInd
Disclosed For Charitable Prps	Yes (1)	DisclosedForCharitablePrpsInd
Agent Trustee Etc	0	AgentTrusteeEtcInd
Incl Escrow Custodial Acct Liab	Yes (1)	InclEscrowCustodialAcctLiabInd
Explanation Provided	Yes (X)	ExplanationProvidedInd

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$9,501,571	BeginningYearBalanceAmt
Contributions	$11,412	ContributionsAmt
Investment Earnings Or Losses	$243,278	InvestmentEarningsOrLossesAmt
Administrative Expenses	$52,231	AdministrativeExpensesAmt
End Year Balance	$9,704,030	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$9,616,660	BeginningYearBalanceAmt
Contributions	$10,356	ContributionsAmt
Investment Earnings Or Losses	-$100,829	InvestmentEarningsOrLossesAmt
Administrative Expenses	$24,616	AdministrativeExpensesAmt
End Year Balance	$9,501,571	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$3,381,374	BeginningYearBalanceAmt
Contributions	$6,271,975	ContributionsAmt
Investment Earnings Or Losses	$11,641	InvestmentEarningsOrLossesAmt
Administrative Expenses	$48,330	AdministrativeExpensesAmt
End Year Balance	$9,616,660	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$3,491,739	BeginningYearBalanceAmt
Contributions	$14,559	ContributionsAmt
Investment Earnings Or Losses	-$83,704	InvestmentEarningsOrLossesAmt
Administrative Expenses	$41,220	AdministrativeExpensesAmt
End Year Balance	$3,381,374	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$3,498,900	BeginningYearBalanceAmt
Contributions	$15,153	ContributionsAmt
Investment Earnings Or Losses	$25,879	InvestmentEarningsOrLossesAmt
Administrative Expenses	$48,193	AdministrativeExpensesAmt
End Year Balance	$3,491,739	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Board Designated Balance EOY	0.64500	BoardDesignatedBalanceEOYPct
Prmnnt Endowment Balance EOY	0.31880	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.03620	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	0	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	0	EndowmentsHeldRelatedOrgInd

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$692,845	OtherCostOrOtherBasisAmt
Depreciation	$650,240	DepreciationAmt
Book Value	$42,605	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$42,605	TotalBookValueLandBuildingsAmt

Other Liabilities Org OtherLiabilitiesOrgGrp

Field	Value	IRS element (for citing)
Desc	CHARITABLE GIFT ANNUITY	Desc
Amt	$150,542	Amt

Field	Value	IRS element (for citing)
Total Liability	$150,542	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$84,602,588	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	$623,106	NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts	$253,020	DonatedServicesAndUseFcltsAmt
Revenue Not Reported	$876,126	RevenueNotReportedAmt
Revenue Subtotal	$83,726,462	RevenueSubtotalAmt
Other Revenues Not Included	-$199,320	OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt	-$199,320	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$83,527,142	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$47,849,806	TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts	$253,020	DonatedServicesUseFcltsAmt
Other Expenses Included	$199,320	OtherExpensesIncludedAmt
Expenses Not Reported	$452,340	ExpensesNotReportedAmt
Expenses Subtotal	$47,397,466	ExpensesSubtotalAmt
Expenses Not Rpt Fincl Stmt	$0	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$47,397,466	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (5 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART IV, LINE 2B:	AS OF 12/31/2016, THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH, INC HELD $453,876 IN AGENCY FUNDS FOR FUTURE DISTRIBUTIONS TO THE NATIONAL INSTITUTES OF HEALTH (NIH). THESE FUNDS ARE DESIGNATED BY THE FUNDER(S) FOR SPECIFIC PROJECTS AT THE NIH, AND WILL BE DISBURSED AS NEEDED.
PART V, LINE 4:	THE FOUNDATION'S ENDOWMENTS CONSIST OF INDIVIDUAL DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR A VARIETY OF PURPOSES. (E.G. VARIETY OF RESEARCH AND EDUCATIONAL INITIATIVES AT THE FOUNDATION FOR THE NIH, INC). NET ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OR DONOR-IMPOSED RESTRICTIONS.
PART X, LINE 2:	THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE; ACCORDINGLY, THE ACCOMPANYING FINANCIAL STATEMENTS DO NOT REFLECT A PROVISION OR LIABILITY FOR FEDERAL AND STATE INCOME TAXES. THE FOUNDATION HAS DETERMINED THAT IT DOES NOT HAVE ANY MATERIAL UNRECOGNIZED TAX BENEFITS OR OBLIGATIONS AS OF DECEMBER 31, 2016 AND 2015.
PART XI, LINE 4B - OTHER ADJUSTMENTS:	FUNDRAISING DIRECT EXPENSE -199,320.
PART XII, LINE 2D - OTHER ADJUSTMENTS:	FUNDRAISING DIRECT EXPENSE 199,320.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (2 entries)

RegionRegionTxt	OfficesOfficesCnt	EmployeeEmployeeCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
EUROPE	0	0	GRANTMAKING	$933,111
SOUTH ASIA	0	0	GRANTMAKING	$286,157

Field	Value	IRS element (for citing)
Subtotal Offices	0	SubtotalOfficesCnt
Subtotal Employees	0	SubtotalEmployeesCnt
Continutation Total Office	0	ContinutationTotalOfficeCnt
Continutation Total Employee	0	ContinutationTotalEmployeeCnt
Total Office	0	TotalOfficeCnt
Total Employee	0	TotalEmployeeCnt
Subtotal Spent	$1,219,268	SubtotalSpentAmt
Continuation Spent	$0	ContinuationSpentAmt
Total Spent	$1,219,268	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (6 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt
SOUTH ASIA	MALNUTRITION & ENTERIC DISEASES NETWORK	$144,394	WIRE TRANSFER
SOUTH ASIA	MALNUTRITION & ENTERIC DISEASES NETWORK	$101,856	WIRE TRANSFER
EUROPE	AMP-T2 DIABETES	$732,435	WIRE TRANSFER
EUROPE	AMP-T2 DIABETES	$85,341	WIRE TRANSFER
SOUTH ASIA	EPIDEMIOLOGY OF VISCERAL LEISMANIASIS PROJECT	$39,907	WIRE TRANSFER
EUROPE	IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS	$115,335	WIRE TRANSFER

Field	Value	IRS element (for citing)
Total501c3 Org	5	Total501c3OrgCnt
Total Other Org	1	TotalOtherOrgCnt
Transfer To Foreign Corp	0	TransferToForeignCorpInd
Interest In Foreign Trust	0	InterestInForeignTrustInd
Foreign Corp Ownership	0	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	0	PassiveForeignInvestmestCoInd
Foreign Partnership	0	ForeignPartnershipInd
Boycott Countries	0	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2:	FormAndLineReferenceDesc
Explanation	PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS SOME DEVELOPING COUNTRY INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS.	ExplanationTxt

Schedule G IRS990ScheduleG

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	2016 FNIH AWARD CEREMONY	Event1Nm
Gross Receipts Event1	$279,800	GrossReceiptsEvent1Amt
Charitable Contri Event1	$15,500	CharitableContriEvent1Amt
Gross Revenue Event1	$264,300	GrossRevenueEvent1Amt
Food And Beverage Event1	$13,000	FoodAndBeverageEvent1Amt
Other Direct Expenses Event1	$186,320	OtherDirectExpensesEvent1Amt
Gross Receipts Total	$279,800	GrossReceiptsTotalAmt
Charitable Contributions Tot	$15,500	CharitableContributionsTotAmt
Gross Revenue Total Events	$264,300	GrossRevenueTotalEventsAmt
Food And Beverage Total Events	$13,000	FoodAndBeverageTotalEventsAmt
Oth Direct Expnss Total Events	$186,320	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$199,320	DirectExpenseSummaryEventsAmt
Net Income Summary	$64,980	NetIncomeSummaryAmt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (25 entries)

Address Line1USAddress/AddressLine1Txt	Address Line2USAddress/AddressLine2Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Purpose Of GrantPurposeOfGrantTxt
CASE WESTERN RESERVE UNIVERSITY
NORD HALL SUITE 615 10900 EUCLID	AVENUE	CLEVELAND	OH	44106	341018992	501(C)(3)	$338,537	CTVIMC2-MOLECULAR IMMUNE CORRELATES CORE
CATALYSIS FOUNDATION FOR HEALTH INC
1900 POWELL STREET SUITE 600		EMERYVILLE	CA	94608	208602047	501(C)(3)	$81,141	PREDICT TB
SUTTER BAY HOSPITALS DBA CALIFORNIA PACIFIC MEDICAL CENTER
475 BRANNAN STREET SUITE 220		SAN FRANCISCO	CA	94107	940562680	501(C)(3)	$63,480	SARCOPENIA
DONALD DANFORTH PLANT SCIENCE CENTER
975 NORTH WARSON ROAD		ST LOUIS	MO	63132	311584621	501(C)(3)	$494,937	REGULATORY DEVELOPMENT FOR HEG-MODIFIED MOSQUITOES
DUKE UNIVERSITY
2200 WEST MAIN STREET SUITE 820	ERWIN SQUARE PLAZA	DURHAM	NC	27705	560532129	501(C)(3)	$166,655	PROFICIENCY TESTING CENTRAL/CTVIMC2
FRED HUTCHINSON CANCER RESEARCH CENTER
1100 FAIRVIEW AVE N		SEATTLE	WA	98109	237156071	501(C)(3)	$276,523	CTVIMC2/INNATE AND MUCOSAL IMMUNITY DISCOVERY TEAM
FRIENDS OF CANCER RESEARCH
1800 M STREET NW SUITE 1050 SOUTH		WASHINGTON	DC	20036	521983273	501(C)(3)	$150,000	LUNGCANCER PROTOCOL
HENRY JACKSON FOUNDATION (USMHRP)
1401 ROCKVILLE PIKE SUITE 600		ROCKVILLE	MD	20852	521317896	501(C)(3)	$108,516	PROFICIENCY TESTING/MAL-ED
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PLACE		NEW YORK	NY	10029	136171197	501(C)(3)	$138,240	AMP-T2 DIABETES-AMP AD
JOHNS HOPKINS UNIVERSITY
615 N WOLFE ST W1100		BALTIMORE	MD	21205	150595110	501(C)(3)	$519,047	MAL-ED/ CARDIAC TROPONIN
NIH- CLINICAL CENTER
9000 ROCKVILLE PIKE		BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$409,690	RESEARCH
NIHOD
9000 ROCKVILLE PIKE		BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$198,200	RESEARCH
NIHNCI
9000 ROCKVILLE PIKE		BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$1,017,902	RESEARCH
NIHNHLBI
9000 ROCKVILLE PIKE		BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$395,919	RESEARCH
NIHNIA
9000 ROCKVILLE PIKE		BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$917,915	RESEARCH
NIHNIAAA
9000 ROCKVILLE PIKE		BETHESDA	MD	20892	520858116	170(C)(1) GOVT	$4,831,999	RESEARCH
NIHNIAID
9000 ROCKVILLE PIKE		BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$3,525,621	RESEARCH
NIHNIAMS
9000 ROCKVILLE PIKE		BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$1,860,000	RESEARCH
NIHNIMH
9000 ROCKVILLE PIKE		BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$973,456	RESEARCH
NIHNINDS
9000 ROCKVILLE PIKE		BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$2,780,620	RESEARCH
REGENTS OF THE UNIVERSITY OF MICHIGAN
3003 SOUTH STATE STREET 1040	WOLVERINE TOWER	ANN ARBOR	MI	48109	386006309	170(C)(1) GOVT	$1,792,113	AMP-T2 DIABETES. DEPOSIT OF METSIM AND FUSION DATA INTO KNOWLEDGE PORTAL
THE PENNYSLVANIA STATE UNIVERSITY
401 RIDER BLDG 227 W BEAVER AVE		STATE COLLEGE	PA	16801	246000376	170(C)(1) GOVT	$37,925	MAL-ED
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
MISSION HALL 550 16TH STREET 2ND	FLOOR	SAN FRANCISCO	CA	94143	946036493	501(C)(3)	$140,010	BONE QUALITY
UNIVERSITY OF SOUTHERN CALIFORNIA
SOTO STREET BUILDING 2001 SOTO	STREET	LOS ANGELES	CA	900899235	911642394	501(C)(3)	$436,394	HD-SCA
UNIVERSITY OF VIRGINIA
PO BOX 400195		CHARLOTTESVILLE	VA	22904	546001796	170(C)(1) GOVT	$344,250	MAL-ED

Field	Value	IRS element (for citing)
Total501c3 Org	25	Total501c3OrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp

Field	Value	IRS element (for citing)
Grant Type	AWARDS	GrantTypeTxt
Recipient	6	RecipientCnt
Cash Grant	$8,100	CashGrantAmt
Valuation Method Used	FMV	ValuationMethodUsedDesc

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2:	FormAndLineReferenceDesc
Explanation	PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS FOR-PROFIT INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS. THE CLINICAL RESEARCH TRAINING PROGRAM (CRTP) IS OPEN TO ALL THIRD YEAR STUDENTS ENROLLED IN MEDICAL OR DENTAL SCHOOLS. THE WOMEN'S HEALTH FELLOWSHIP PROGRAMS ARE OPEN TO DOCTORAL-LEVEL CANDIDATES WITHIN FIVE YEARS OF RECEIPT OF THE DOCTORAL DEGREE. APPLICATIONS, CONTAINING TRANSCRIPTS AND ESSAYS ON THEIR RESEARCH GOALS ARE SUBMITTED AND REVIEWED BY PANELS OF NIH SCIENTISTS WHO MAKE RECOMMENDATIONS FOR SELECTION. POTENTIAL FELLOWS ARE OFTEN BROUGHT TO THE CAMPUS FOR INTERVIEWS AND FINAL SELECTION. THE FOUNDATION'S FELLOWSHIPS ARE OPEN TO PROFESSIONALS WORKING AT VARIOUS STAGES OF THEIR RESEARCH CAREERS. APPLICANTS TO THE NEUROSCIENCE FELLOWSHIP, FOR EXAMPLE, ARE YOUNG SCIENTISTS WHO WILL BENEFIT FROM EXPERIENCE OF CLINICAL AND BASIC SCIENCE RESEARCH. THE DIRECTOR'S FELLOWSHIP IN COMPLEMENTARY AND ALTERNATIVE MEDICINE RESEARCH SEEKS A MORE EXPERIENCED SCIENTIST WHO IS WELL-POSITIONED TO BECOME A LEADER IN THE FIELD OF COMPLEMENTARY ALTERNATIVE MEDICINE.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Written Employment Contract	Yes (X)	WrittenEmploymentContractInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	0	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	0	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	0	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	0	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	0	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	0	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	0	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	0	AnyNonFixedPaymentsInd
Initial Contract Exception	0	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (11 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
DR MARIA C FREIRE
PRESIDENT AND EXECUTIVE DIRECTOR	$406,597	$0	$0	$0	$0	$0	$26,500	$0	$0	$0	$433,097	$0	$0	$0
DR STEPHANIE JAMES
DIRECTOR OF SCIENCE	$305,588	$0	$0	$0	$0	$0	$26,500	$0	$0	$0	$332,088	$0	$0	$0
MR DAVID WHOLLEY
DIRECTOR OF RESEARCH PARTNERSHIPS	$299,438	$0	$0	$0	$2,550	$0	$26,500	$0	$11,535	$0	$340,023	$0	$0	$0
MS JULIE TUNE
CHIEF FINANCIAL OFFICER	$201,181	$0	$0	$0	$500	$0	$20,168	$0	$11,535	$0	$233,384	$0	$0	$0
MS JULIA WOLF-RODDA
DIRECTOR OF DEVELOPMENT	$197,264	$0	$0	$0	$2,000	$0	$19,926	$0	$11,535	$0	$230,725	$0	$0	$0
MR KEVIN A KLOCK
DIR. OF OPERATIONS & PRESIDENT ADVIS	$196,684	$0	$0	$0	$2,583	$0	$19,927	$0	$11,535	$0	$230,729	$0	$0	$0
DR JOSEPH MENETSKI
DEPUTY DIRECTOR OF RESEARCH PARTNERS	$200,877	$0	$0	$0	$0	$0	$20,088	$0	$11,439	$0	$232,404	$0	$0	$0
DR KAREN TOUNTAS
SCIENTIFIC PROGRAM MANAGER	$165,024	$0	$4,000	$0	$0	$0	$16,902	$0	$11,535	$0	$197,461	$0	$0	$0
DR MICHAEL GOTTLIEB
ASSOCIATE DIRECTOR OF SCIENCE	$160,295	$0	$0	$0	$0	$0	$16,030	$0	$0	$0	$176,325	$0	$0	$0
DR ROSA CANET AVILES
SCIENTIFIC PROGRAM MANAGER	$155,135	$0	$0	$0	$2,500	$0	$15,763	$0	$11,535	$0	$184,933	$0	$0	$0
MR STEVE HOFFMANN
SCIENTIFIC PROGRAM MANAGER	$144,738	$0	$0	$0	$0	$0	$14,474	$0	$11,535	$0	$170,747	$0	$0	$0

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	2	ContributionCnt
Noncash Contributions Rpt F990	$16,902	NoncashContributionsRptF990Amt
Method Of Determining Revenues	STOCK PRICE	MethodOfDeterminingRevenuesTxt

Drugs And Medical Supplies DrugsAndMedicalSuppliesGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	2	ContributionCnt
Noncash Contributions Rpt F990	$737,668	NoncashContributionsRptF990Amt
Method Of Determining Revenues	MARKET PRICE	MethodOfDeterminingRevenuesTxt

Field	Value	IRS element (for citing)
Any Property That Must Be Held	0	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	0	ReviewProcessUnusualNCGiftsInd
Third Parties Used	0	ThirdPartiesUsedInd

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (7 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PART III, LINE 4A	CONTINUED: CHANGING THE PROGNOSIS OF ALZHEIMER'S DISEASE FIRST DISCOVERED 110 YEARS AGO, ALZHEIMER'S DISEASE STILL HAS NO CURE OR EFFECTIVE TREATMENT. MORE THAN FIVE MILLION AMERICANS SUFFER FROM THIS PROGRESSIVE BRAIN DISORDER, WITH ESTIMATES BY THE NATIONAL INSTITUTE ON AGING (NIA) SUGGESTING IT IS THE THIRD LEADING CAUSE OF DEATH FOR OLDER ADULTS. FOR YEARS, SCIENTISTS HAVE LABORED WITH LIMITED SUCCESS TO FIND BREAKTHROUGHS THAT WOULD AID IN THE DIAGNOSIS AND TREATMENT OF THIS DEVASTATING DISEASE. BUT IN 2004 AN UNPRECEDENTED STUDY CALLED THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI)-WHICH ENTERED ITS THIRD PHASE IN 2016-UNITED SCIENTISTS ACROSS MULTIPLE SECTORS TO CHANGE THE PROGNOSIS FOR DEVELOPING NEW TREATMENTS. "THE PROBLEM IN THE FIELD WAS THAT YOU HAD MANY DIFFERENT SCIENTISTS, IN MANY DIFFERENT UNIVERSITIES, DOING THEIR OWN RESEARCH WITH THEIR OWN PATIENTS AND WITH THEIR OWN METHODS," MICHAEL W. WEINER, M.D., ADNI PRINCIPAL INVESTIGATOR, SAN FRANCISCO DEPARTMENT OF VETERANS AFFAIRS MEDICAL CENTER AND THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, TOLD THE NEW YORK TIMES IN 2010. "WHAT WAS NEEDED WAS TO GET EVERYONE TOGETHER AND TO GET A COMMON DATA SET." ADNI FULFILLED THIS NEED BY BRINGING THE PUBLIC AND PRIVATE SECTORS TOGETHER TO UNCOVER THE BIOLOGICAL MARKERS (BIOMARKERS) THAT TRACK ALZHEIMER'S DISEASE PROGRESSION. THE LONGITUDINAL STUDY USES IMAGING, BIOCHEMICAL AND GENETIC DATA TO IDENTIFY CHANGES TAKING PLACE IN THE BRAINS OF 800 INDIVIDUALS WITH NORMAL COGNITION AND DIFFERENT STAGES OF THE DISEASE. MOST SIGNIFICANTLY, THE DATA ARE MADE IMMEDIATELY AVAILABLE TO RESEARCHERS AT ANY ORGANIZATION. FULFILLING ITS UNIQUE AND INSTRUMENTAL ROLE, THE FNIH BROUGHT ALL OF THE NECESSARY PARTIES TOGETHER. BY THE LAUNCH OF THE FIRST PHASE OF ADNI, NIA CONTRIBUTED $41 MILLION, OTHER NATIONAL INSTITUTES OF HEALTH INSTITUTES PROVIDED $2.4 MILLION AND 20 COMPANIES AND TWO NOT-FOR-PROFIT ORGANIZATIONS DONATED $27 MILLION THROUGH THE FNIH. MORE THAN 30 ORGANIZATIONS HAVE SUPPORTED ADNI SINCE LAUNCH AND RESEARCHERS ARE TRACKING VOLUNTEERS AT 58 CLINICAL SITES IN NORTH AMERICA. THE THIRD PHASE OF ADNI (ADNI3) LAUNCHED IN SEPTEMBER 2016. NIA SUPPORT IS EXPECTED TO TOTAL $40 MILLION OVER THE COURSE OF ADNI3 AND AN ADDITIONAL $20 MILLION IS SOUGHT BY THE FNIH FROM THE PRIVATE SECTOR. ADDITIONS TO ADNI3 INCLUDE RECRUITING MORE PATIENT VOLUNTEERS, USING STATE-OF-THE-ART IMAGING TO MONITOR BRAIN LEVELS OF TAU (A PROTEIN THAT IS OFTEN ABNORMAL IN ALZHEIMER'S PATIENTS) AND PERFORMING CUTTING-EDGE ANALYSES TO ASSESS COMPLEX INTERACTIONS BETWEEN THE BRAIN AND BODY. ADNI3 ALSO WILL ASSESS COGNITIVE FUNCTION THROUGH COMPUTER TESTS AT HOME AND IN THE DOCTOR'S OFFICE. AFTER 12 YEARS, ADNI CONTINUES TO ADVANCE THE FIELD OF ALZHEIMER'S DISEASE, WHILE SERVING AS A MODEL FOR HOW PUBLIC-PRIVATE PARTNERSHIPS CAN LEAD TO OTHERWISE UNATTAINABLE RESEARCH PROGRESS. BY STANDARDIZING TECHNOLOGIES AND PROTOCOLS, ADNI HAS IMPROVED CLINICAL TRIAL DESIGN AND INFLUENCED THE DEVELOPMENT OF OTHER PARTNERSHIPS IN AREAS SUCH AS PARKINSON'S DISEASE AND MULTIPLE SCLEROSIS, AND ITS OPEN-ACCESS DATA POLICY SERVES AS A MODEL OF SUCCESSFUL PRECOMPETITIVE DATA SHARING. ADNI DATA HAVE BEEN DOWNLOADED FOR RESEARCH PURPOSES MORE THAN 14 MILLION TIMES AND SCIENTISTS WORLDWIDE HAVE USED THEM TO PUBLISH MORE THAN 1,200 SCIENTIFIC PAPERS, LEADING TO A BETTER UNDERSTANDING OF THE RELATIONSHIP BETWEEN BIOMARKERS AND ALZHEIMER'S DISEASE PROGRESSION-AND HOPEFULLY, ONE DAY SOON, NEW AND EFFECTIVE TREATMENTS. CELEBRATING 20 YEARS OF PARTNERSHIP AND DISCOVERY (TIMELINE) FOR TWO DECADES, THE FNIH HAS BUILT AND NURTURED SCIENTIFIC PARTNERSHIPS, RAISING NEARLY $1 BILLION TO MAKE IMPORTANT HEALTH DISCOVERIES POSSIBLE. THESE ALLIANCES WITH GOVERNMENT, ACADEMIA, INDUSTRY, PHILANTHROPISTS AND INDIVIDUAL DONORS, ENABLE THE FNIH TO SUPPORT RESEARCHER TRAINING, AWARDS, SYMPOSIA AND PATIENT CARE ACTIVITIES AT THE NATIONAL INSTITUTES OF HEALTH (NIH), IN ADDITION TO FOSTERING INNOVATIVE RESEARCH MODELS THAT PROPEL CUTTING-EDGE SCIENCE. THE FNIH'S SUCCESS IS A TESTAMENT TO THE POWER OF COLLABORATION AMONG DIVERSE STAKEHOLDERS WORKING TO SOLVE PRESSING HEALTH CHALLENGES TOGETHER. AS A TRUSTED RESOURCE FOR THE NIH AND THE SCIENTIFIC COMMUNITY, THE FNIH WILL CONTINUE TO LEAD EFFORTS TO SHAPE THE COURSE OF BIOMEDICAL SCIENCE AND HUMAN HEALTH FOR DECADES TO COME. 1998 - NORMAN P. SALZMAN MEMORIAL SYMPOSIUM AND AWARD IN VIROLOGY: FIRST ANNUAL AWARD IN FNIH HISTORY IS ESTABLISHED; 20 OUTSTANDING FELLOWS HONORED TO DATE. - CLINICAL RESEARCH TRAINING PROGRAM: MAJOR PROGRAM TO TRAIN CLINICIAN SCIENTISTS AT THE NIH IS LAUNCHED. 1999 - OSTEOARTHRITIS INITIATIVE: THE FNIH'S FIRST LARGE RESEARCH PROJECT THAT CREATED A PUBLIC-ACCESS DATABASE THAT ENABLED SCIENTISTS WORLDWIDE TO HELP PREDICT THE PROGRESSION OF OSTEOARTHRITIS AND DEVELOP TREATMENTS, LEADING TO A NEW MODEL FOR COLLABORATION. 2003 - ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI): WITH NEW MODELS FOR COLLABORATIVE RESEARCH AND OPEN DATA ACCESS, THIS STUDY ADVANCES THE UNDERSTANDING OF ALZHEIMER'S DISEASE OVER THE NEXT 12 YEARS. - GRAND CHALLENGES IN GLOBAL HEALTH: A $200 MILLION PARTNERSHIP WITH THE BILL & MELINDA GATES FOUNDATION TO FIGHT DISEASES IN THE WORLD'S POOREST COUNTRIES. 2005 - THE EDMOND J. SAFRA FAMILY LODGE: THIS HOME-AWAY-FROM-HOME FOR PATIENTS OF THE NIH CLINICAL CENTER AND THEIR FAMILIES OPENS. MORE THAN 110,000 ROOM NIGHTS HOSTED TO DATE. - GENETIC ASSOCIATION INFORMATION NETWORK (GAIN): SAMPLES FROM THOUSANDS OF PATIENTS IN SIX COMMON DISEASES ARE SEQUENCED AND COMPILED IN THE FIRST LARGE-SCALE INDIVIDUAL GENOTYPE-PHENOTYPE DATABASE (DBGAP) AT THE NATIONAL LIBRARY OF MEDICINE. - COMPREHENSIVE T-CELL VACCINE IMMUNE MONITORING CONSORTIUM (CTC-VIMC): A NETWORK ACROSS THREE CONTINENTS THAT PROVIDES RESEARCHERS WITH TOOLS TO EVALUATE PATIENTS FOR HIV/ AIDS VACCINES. 2006 - THE BIOMARKERS CONSORTIUM: THIS LANDMARK PUBLIC-PRIVATE PARTNERSHIP LAUNCHES TO ADVANCE THE QUALIFICATION OF NEW BIOMARKERS USED IN DRUG DEVELOPMENT AND APPROVALS. 2007 - OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP (OMOP): A PARTNERSHIP THAT STUDIES ADVERSE DRUG REACTIONS TO HELP IMPROVE THE SAFETY OF MEDICAL PRODUCTS. 2008 - MAL-ED: A LONGITUDINAL STUDY THAT EXAMINES THE RELATIONSHIPS BETWEEN MALNUTRITION AND INTESTINAL DISEASES AND THEIR EFFECT ON THE HEALTH AND DEVELOPMENT OF YOUNG CHILDREN. - VECTOR-BASED CONTROL OF TRANSMISSION: DISCOVERY RESEARCH (VCTR): A PROGRAM THAT DEVELOPS NOVEL TECHNOLOGIES TO STOP THE SPREAD OF MOSQUITO-BORNE DISEASES. 2012 - SPORTS AND HEALTH RESEARCH PROGRAM (SHRP): A PARTNERSHIP THAT ACCELERATES RESEARCH ON MEDICAL CONDITIONS PROMINENT IN ATHLETES, SUCH AS TRAUMATIC BRAIN INJURY. - MEDICAL RESEARCH SCHOLARS PROGRAM (MRSP): THIS INTENSIVE RESIDENTIAL TRAINING PROGRAM BEGINS AT THE NIH FOR MEDICAL, DENTAL AND VETERINARY STUDENTS. 2013 - LURIE PRIZE IN BIOMEDICAL SCIENCES: ESTABLISHMENT OF THIS ANNUAL AWARD THAT RECOGNIZES OUTSTANDING ACHIEVEMENTS BY A YOUNG BIOMEDICAL RESEARCHER. - ACCELERATING MEDICINES PARTNERSHIP (AMP): A $190 MILLION PARTNERSHIP THAT SEEKS TO IDENTIFY AND VALIDATE NEW DRUG TARGETS IN ALZHEIMER'S DISEASE, TYPE 2 DIABETES AND IMMUNE-MEDIATED DISORDERS. - GENOME: UNLOCKING LIFE'S CODE: THE FNIH FUNDS THIS HUMAN GENOMICS EXHIBIT, WHICH IS NOW ON A FOUR-YEAR NORTH AMERICAN TOUR. - ELIMINATE DENGUE: A PROJECT THAT USES A COMMON BACTERIUM TO HELP STOP THE SPREAD OF VIRAL DISEASES BY MOSQUITOES. 2014 - LUNGMAP: A PRECISION MEDICINE TRIAL THAT TESTS MULTIPLE GENETICALLY-TARGETED DRUGS AND IMMUNOTHERAPIES. 2016 - EVIDENTIARY CRITERIA FRAMEWORK: THE FNIH BIOMARKERS CONSORTIUM WORKS WITH THE NIH AND FDA TO DEVELOP STANDARDS FOR THE LEVELS OF EVIDENCE REQUIRED TO QUALIFY BIOMARKERS FOR USE IN DRUG DEVELOPMENT. - CHARLES A. SANDERS, M.D., PARTNERSHIP AWARD: AN ANNUAL AWARD THAT RECOGNIZES PERSONS AND/ OR ORGANIZATIONS THAT MAKE SIGNIFICANT CONTRIBUTIONS IN SUPPORT OF THE FNIH'S MISSION.
FORM 990, PART VI, SECTION A, LINE 2	DR. FREIRE, PRESIDENT OF THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH, INC. (FNIH), IS A NON-EXECUTIVE MEMBER OF THE BOARD OF DIRECTORS OF ALEXANDRIA REAL ESTATE EQUITIES (ARE). MR. JOEL MARCUS, CEO AND CHAIRMAN OF ARE IS A NON-EXECUTIVE MEMBER OF THE FNIH BOARD OF DIRECTORS.
FORM 990, PART VI, SECTION B, LINE 11B	PRIOR TO THE SUBMISSION OF THE FOUNDATION FOR NIH'S FORM 990 TO THE INTERNAL REVENUE SERVICE, EACH VOTING MEMBER OF THE BOARD OF DIRECTORS SHALL BE PROVIDED WITH A COPY OF THE FINAL FORM 990 AS APPROVED BY THE CHIEF FINANCIAL OFFICER. BOARD DIRECTORS SHALL BE PROVIDED WITH AT LEAST TEN BUSINESS DAYS TO REVIEW THE FORM AND RAISE QUESTIONS, MAKE SUGGESTIONS, AND ADDRESS ANY POTENTIAL PROBLEMS OR CONCERNS WITH THE CHIEF FINANCIAL OFFICER. A SPECIAL MEETING OF THE GOVERNANCE COMMITTEE WILL BE CALLED TO REVIEW THE SUGGESTED CHANGES FROM THE BOARD OF DIRECTORS AND TO APPROVE THE FINAL VERSION OF THE FORM 990 FOR SUBMISSION.
FORM 990, PART VI, SECTION B, LINE 12C	THE FOUNDATION REQUIRES DIRECTORS, OFFICERS, VOLUNTEER COMMITTEE MEMBERS, AND STAFF MEMBERS TO DISCLOSE REAL AND APPARENT CONFLICTS OF INTEREST FOR THEMSELVES AND THEIR FAMILY MEMBERS AND TO ANNUALLY SIGN A STATEMENT OF COMPLIANCE. AFTER A CONFLICT OR AN APPARENT CONFLICT OF INTEREST HAS BEEN DISCLOSED, THE BOARD OF DIRECTORS OR THE BOARD COMMITTEE, OR THEIR DESIGNEE, IN THE ABSENCE OF THE INTERESTED PERSON, SHALL DETERMINE IF THE CONFLICT OF INTEREST OR THE APPEARANCE OF A CONFLICT OF INTEREST EXISTS AND IS MATERIAL AND WILL DECIDE HOW IT IS TO BE MANAGED OR ELIMINATED.
FORM 990, PART VI, SECTION B, LINE 15	BEGINNING IN 2015, THE NEWLY CREATED COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS WILL REVIEW AND APPROVE THE SALARIES OF THE EXECUTIVE DIRECTOR AND KEY EMPLOYEES ANNUALLY.
FORM 990, PART VI, SECTION C, LINE 19	ALL DOCUMENTS ARE AVAILABLE UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS ARE POSTED TO THE ORGANIZATION'S WEBSITE.
FORM 990, PART XII, LINE 2C:	PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.